54 results about "Asparaginase" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of asparaginase in preparation of a medicine for treating pancreatic cancer. The asparaginase and the gemcitabine are combined for treating pancreatic cancer, and results show that the combination of the two medicines can promote apoptosis of pancreatic cancer cells, reduce proliferation and reduce activation of pancreatic stellate cells, so that an important scientific basis is provided for improving gemcitabine drug resistance, and meanwhile, a new application is provided for the asparaginase.

To provide use methods of compositions in drug production for inhibiting cancer cells having low asparagine synthetase (ASNS) expression.SOLUTION: The disclosure relates to a use method of a composition comprising an arginine reducing compound and an asparagine reducing compound for preparing a medicament to inhibit a cancer cell, where an arginase being the arginine reducing compound is specifically effective in combination use with an asparaginase being the arginine reducing compound for inhibiting proliferation of cancer cells, in particular, cells having low ASNS expression. Further, the medicament comprises a compound that reduces glutamine concentration such as an aminotransferase inhibitor.SELECTED DRAWING: Figure 1

Various embodiments are provided relating to variant asparaginase polypeptides having enhanced stability, pharmacodynamics and / or reduced immunogenicity. The variant asparaginase polypeptides can be used as therapeutic agents in mammals including humans, canines, felines and equines.

The present invention relates to improved preparation and delivery of asparaginase for pharmaceutical use (eg, human and veterinary medicine).

The invention relates to the technical field of food processing, in particular to a method for reducing the acrylamide content of infant bakery products. The preparation method comprises the following steps: dissolving a liquid asparaginase dissolving solution into water and pear juice, uniformly mixing, adding the mixture into a rice flour raw material, kneading, forming, drying, standing, baking and the like to obtain a baked product which is fluffy in cake blank, easy to melt in saliva and fresh and sweet in taste. And the addition amount of the liquid asparaginase is 280 to 1100 ppm. The method has the beneficial effects that the problem that the acrylamide content of infant baking complementary food in the existing market is too high is solved, the acrylamide limit is reduced on the basis that the taste and flavor of the product are not influenced, the risk is reduced, and the risk monitoring standard of European Union is met at the same time.

To provide a technology to suppress unpleasant odors and tastes of beans.SOLUTION: An unpleasant odor and taste suppressing agent contains exopeptidase as an active ingredient and suppresses one or more of bean odors, bitterness of beans, and harsh taste of beans. According to the present invention, unpleasant odors and taste originating from beans can be suppressed through a simple process of contacting beans or their processed products with exopeptidase, endopeptidase, and / or asparaginase, thereby enhancing the commercial value of food products containing beans.SELECTED DRAWING: Figure 2

The present invention provides a low-immunogenicity asparaginase mutant, in which T119 of wild-type asparaginase type II is replaced by C, K196 is replaced by A, Y218 is replaced by D or C or E, Y220 is replaced by A, and Y289 is replaced by R or G or K; and a preparation method and application thereof are provided. Compared with the prior art, the present invention has the following advantages: the low-immunogenicity asparaginase mutant provided by the present invention, its preparation method and application, comprehensively considered, the asparaginase mutant prepared by this preparation method has high yield, high purity, high safety and low cost, and at the same time, its immunogenicity is effectively reduced by mutation, avoiding progressive immune response and systemic allergic reaction.

The invention relates to methods of inhibiting hair growth in a subject, the method comprises administering an inhibitor of lactic acid fermentation to the subject, wherein the inhibitor is selected from the group consisting of pyruvate dehydrogenase kinase inhibitor, desoxyrhapontigenin, a phosphofructokinases inhibitor, a thioredoxin-1 inhibitor, L- Asparaginase, a GLUT1 inhibitor, a glutaminase C inhibitor, a hexokinase inhibitor and an mTORCI and mTORC2 inhibitor. Also provided herein are compositions for inhibiting hair growth and methods of screening for inhibitors of hair growth.

The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.

Provided are novel recombinant fusion proteins comprising asparaginase portion fused with an albumin-binding portion. The long-acting recombinant fusion proteins are able to deplete both asparagine and glutamine upon administration to a subject in need thereof, enabling these proteins to be used in the treatment of disease treatable by asparagine and / or glutamine depletion, such as gastric cancer, and food treatment.

The present disclosure provides an analyte sensor for use in detecting potassium. In certain embodiments, an analyte sensor of the present disclosure includes at least two asparagine-responsive active areas, where each asparagine-responsive active area includes an asparaginase that exhibits a particular potassium dependency. In certain embodiments, an analyte sensor of the present disclosure includes at least two aspartate-responsive active areas, where each aspartate-responsive active area includes an aspartate oxidase that exhibits a particular potassium dependency. The present disclosure further provides methods for monitoring potassium levels, e.g., in vivo potassium levels, using the disclosed analyte sensors.

2 Methods of Treatment with Asparaginase Abstract The invention relates to methods of treating diseases with L-asparaginase. Methods of Treatment with Asparaginase Abstract The invention relates to methods of treating diseases with L-asparaginase. 2 20 24 27 82 86 11 D ec 2 02 4 2 0 2 4 A b s t r a c t 2 0 2 4 2 7 8 2 8 6 1 1 D e c 2

The invention discloses a method for improving enzymolysis peculiar smell of dairy products and application, and belongs to the technical field of dairy product processing. The method comprises the following steps: carrying out enzymolysis on raw milk by using composite protease consisting of excision protease and asparaginase, carrying out secondary enzymolysis by using an alcohol-containing system, and finally inactivating the enzyme, so as to improve the enzymolysis odor of the dairy product. By adopting the compound enzyme preparation with a specific ratio and optimizing an alcohol-containing system and enzymolysis process conditions, undesirable flavors such as saponification flavor, grease rancidity flavor or bitter taste and the like which are easily generated in a single enzymolysis process are effectively avoided. The method is suitable for preparing the flavored dairy products.

Compositions and methods for the preparation of high purity arginase and high efficiency preparation of monosubstituted polyethylene glycol conjugation of arginase are provided, as are methods for using arginase in combination with asparaginase to inhibit cancer cells. High purity arginase is provided by applying an initial high temperature precipitation step, followed by ion exchange to provide arginase at a purity of 90% or greater. Conjugation with either linear or branched polyethylene glycol is performed using a maleimide-derivatized polyethylene glycol at low molar excess relative to arginase and at reduced temperature. Such polyethylene glycol-derivatized arginase is useful in combination with asparaginase in inhibiting the growth of cancer cells, particularly cells that have low endogenous asparaginase expression.

Extranodal natural killer / T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achieve long-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase R has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL.

Described herein are methods and compositions for treating cancer. Aspects of the invention relate to determining if a biological sample obtained from a subject for GSK3α bodies (puncta), e.g., in response to asparaginase treatment, and administering to a subject having cancer an asparaginase and an agent that inhibits GSK3α to a subject who has been identified as forming GSK3α-positive bodies.

To provide a novel protein deamidation enzyme (protein asparaginase) that catalyzes a reaction of deamidation of an asparagine residue contained in a protein.SOLUTION: A protein characterized by having activity to catalyze a reaction in which an asparagine residue in a protein is deamidated, and by having one β-barrel domain at the C-terminus or having no β-barrel domain at the C-terminus.SELECTED DRAWING: Figure 1

The present disclosure provides compositions and methods for treating cancer in a human subject comprising dosing a human subject with a monotherapy or combination therapy involving L-asparaginase. Combination therapies disclosed herein include combination therapies with functionalized or unfunctionalized L-asparaginase in combination with a BCL-XL inhibitor, a BCL-2 inhibitor, a CD20 inhibitor, an mTOR inhibitor, or another anticancer agent.

The present disclosure provides an analyte sensor for use in detecting potassium. In certain embodiments, an analyte sensor of the present disclosure includes at least two asparagine-responsive active areas, where each asparagine-responsive active area includes an asparaginase that exhibits a particular potassium dependency. In certain embodiments, an analyte sensor of the present disclosure includes at least two aspartate-responsive active areas, where each aspartate-responsive active area includes an aspartate oxidase that exhibits a particular potassium dependency. The present disclosure further provides methods for monitoring potassium levels, e.g., in vivo potassium levels, using the disclosed analyte sensors.

Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an asparaginase and an agent that inhibits GSK3ƒ. Another aspect of the invention relates to administering an asparaginase to a subject having cancer that comprises an inactivating mutation in GSK3ƒ.

The invention provides a method for preparing and separating L-asparaginic acid and a byproduct ammonium sulfate thereof by an enzyme method. The method comprises the following steps: step 1, reacting fumaric acid with ammonia to prepare an ammonium fumarate aqueous solution; and 2, continuously pumping the ammonium fumarate solution into a reactor filled with L-asparaginase resin particles, and carrying out a continuous flow circular reaction in the reactor. 3, after the reaction endpoint is detected, decolorizing the reaction solution, adding sulfuric acid to adjust the pH value, separating out L-asparaginic acid, and carrying out solid-liquid separation to obtain a solid and a mother solution; the L-asparaginase resin particles are prepared through the following steps that A, a strain is inoculated into a shake flask culture medium to be cultured, then the culture is gradually enlarged to the scale of a fermentation tank, centrifugation is conducted, and L-asparaginase solids are collected; and B, adding the L-asparaginase solid and the resin into water to obtain the L-asparaginase resin particles with the particle size of 5-8 mm. According to the method provided by the invention, the L-asparaginase resin particles can be recycled, and the enzyme fermentation liquid does not enter the L-asparaginic acid production liquid, so that the quality of the finished product is improved.

The invention discloses a method for improving sensory quality of raw milk by using composite enzymatic hydrolysis and application, and belongs to the technical field of dairy product processing. The method comprises the following steps: carrying out enzymolysis on raw milk by using compound protease consisting of excision protease and asparaginase, carrying out enzymolysis by using lipase, and finally inactivating the enzyme, so as to improve the sensory quality of the raw milk. According to the invention, the complex enzyme preparation with a specific ratio is adopted, and the enzymolysis process conditions are optimized, so that the bad flavors such as saponification flavor, grease rancidity flavor or bitter taste which are easily generated in a single enzymolysis process are effectively avoided. According to the method, the sensory quality of the raw milk can be remarkably improved, so that the raw milk has a complex and rich taste similar to that of fermented milk. The method is suitable for preparing the flavored dairy products.

The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.

Embodiments of the present invention include polyalkylene oxide-asparaginase compositions. In some instances, the composition is a lyophilized, storage-stable composition. In some instances, the lyophilized composition includes one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods for making the composition. The composition finds use in a variety of applications, including, for example, treating a neoplastic condition in a subject.

The invention relates to application of asparaginase in preparation of anti-inflammatory drugs, and belongs to the technical field of biological medicines. The invention discovers and discloses a new application of asparaginase in preparation of anti-inflammatory drugs for the first time. Experiments prove that the asparaginase affects the combination of asparaginase and an important linker molecule TBK1 in innate immunity by reducing the content of asparaginase in cells; according to the present invention, the asparaginase is used as the anti-inflammatory drug, and further influences the aggregation and the trans-self-phosphorylation of TBK1, such that the kinase activity of TBK1 is reduced, and the activation of the TBK1 downstream signal channel is inhibited, such that the generation of IFN-beta in the macrophage after DNA virus and RNA virus infection is significantly reduced, the replication of DNA and RNA viruses in the macrophage is promoted, and the specific anti-inflammatory effect of the asparaginase is proved, and the asparaginase can be used for preparing the anti-inflammatory drug.

The invention relates to the technical field of food preparation, in particular to application of enzymolysis, a pulsed electric field and a compound natural spice extract in preparation of chili oil with low acrylamide content. The method comprises the following steps: firstly, pretreating a chili raw material by combining a pulsed electric field with asparaginase enzymolysis, then preparing the chili oil chili from the treated chili, and adding a compound natural spice extract into the chili oil chili to inhibit the generation of acrylamide. The process disclosed by the invention can effectively reduce the content of acrylamide in the chili oil. The prepared chili oil chilies are healthier, red and bright in color, spicy, hot, fresh and fragrant.

The present invention relates to a method for producing roasted coffee beans comprising treating raw coffee beans with steam followed by contacting with asparaginase.

The present invention discloses a type II L-asparaginase and its application, and relates to the field of genetic engineering technology. The amino acid sequence of the enzyme is shown in SEQ ID NO.4, and the nucleotide sequence of the gene encoding the enzyme is shown in SEQ ID NO.3. The type II L-asparaginase provided by the present invention has an optimum temperature of 45°C, an optimum pH of 8.0, and has a high specific activity of 598.907U / mg, a half-life of 102h in animal serum at 37°C, and a T of 1.57kcal / cm3 in trypsin. 1 / 2 =33min, the enzyme has no glutaminase activity. The enzyme can induce apoptosis of human liver cancer cell line QGY-7703 and human malignant melanoma cell line A-375, IC 50 The concentrations of 5.7 and 6.5 U / mL respectively, and it will not cause hemolysis. The enzyme has potential application value in the pharmaceutical industry.

The present invention relates to a novel fusion protein in which a monobody specifically bidning to a tumor antigen is linked to L-asparaginase for treating solid cancer more efficiently, and a use thereof, paticularly to a novel fusion protein comprising a recombinant monobody which specifically binds to clareticulin and an L-asparaginase linked to the C-terminus of the recombinant monobody, wherein the recombinant monobody has a peptide that specifically binds to the calreticulin inserted into at least one of the BC loop and the FG loop of human fibronectin domain III (Fn3) as an asparaginase-based novel anticancer agent targeting tumor antigen whose drug delivery efficacy to tumor tissue is enhanced.